Description
Indication & Scope
Sintilimab Injection (Tyvyt®) is a fully human anti-PD-1 monoclonal antibody. It binds to PD-1 on T cells, blocks PD-1/PD-L1 immune checkpoint pathway, restores T cell anti-tumor immune function, activates systemic anti-tumor immunity to kill cancer cells.
- Mechanism
Block PD-1 checkpoint pathway, restore T cell anti-tumor immune activity - Drug class
PD-1 Immune Checkpoint Inhibitor / Monoclonal Antibody Anti-tumor Immunotherapy - Clinical use
Multiple malignant tumors including classical Hodgkin’s lymphoma, non-small cell lung cancer, hepatocellular carcinoma, esophageal and gastric cancer
| Generic Name | Sintilimab Injection |
| Brand Name | Tyvyt® |
| Ingredient | Sintilimab |
| Dosage Form | Injection |
| Package | 10ml:100mg/vial |
| Conditions Treated | Relapsed/refractory classical Hodgkin’s lymphoma after ≥2 lines chemotherapy;First-line combined chemotherapy for non-squamous/squamous non-small cell lung cancer;First-line combined therapy for unresectable/metastatic hepatocellular carcinoma;First-line combined therapy for esophageal squamous cell carcinoma, gastric/gastroesophageal junction adenocarcinoma |
| Taboos | Hypersensitivity to sintilimab or any excipients |
| Place of origin | Jiangsu,China |
| Priscription Type | Prescription Drug, Class B Medicare |
| Storage Conditions | Store at 2℃-8℃, protected from light, do not freeze |
| Manufacturer | Innovent Biologics (Suzhou) Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | S20180016 |
| Date of Revision | January 12, 2026 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: 200mg, intravenous infusion, once every 3 weeks; some indications use weight-based dosage (3mg/kg q3w); given over 30–60 minutes, do not rapid bolus
Time: Intravenous slow infusion over 30–60 minutes, do not give as rapid IV push
Interaction: Risk of severe immune-related adverse events when combined with immunosuppressants/corticosteroids; monitor closely; do not mix directly with other infusions
Side effects: Immune-related adverse reactions (thyroid dysfunction, pneumonitis, hepatitis, colitis), fever, fatigue, anemia, infusion reactions, elevated liver enzymes, myelosuppression
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
How is the drug administered?
Intravenous infusion over 30–60 minutes, 200mg once every 3 weeks.
Can other medicines be mixed directly in the same infusion bag with Sintilimab Injection?
No, do not mix with other drugs directly.
What is the core target of sintilimab?
PD-1 (programmed death receptor 1) on T lymphocytes.
What to do for severe immune adverse reactions?
Pause or permanently discontinue the drug and give corticosteroid treatment.
Tyvyt® | Sintilimab Injection | Hodgkin’s Lymphoma,Hepatocellular Carcinoma and NSCLC | DengYueRX
INN: Sintilimab
Indications: Hodgkin’s Lymphoma,Hepatocellular Carcinoma and NSCLC (non-small cell lung cancer)
Dosage Form: Injection
Strength: 10ml:100mg/Vial
Original price was: $268.49.$228.21Current price is: $228.21.
